Prevalence and risk of gingival enlargement in patients treated with anticonvulsant drugs

European Journal of Clinical Investigation

Volumn 31, Issue 9, 2001, Pages 781-788

  Brunet, L ^a   Miranda, J ^a   Roset, P ^b   Berini, L ^a   Farre M ^b   Mendieta, C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Antiepileptics; Gingival overgrowth; Phenytoin; Risk factors

Indexed keywords

ANTICONVULSIVE AGENT; PHENYTOIN;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GINGIVA HYPERPLASIA; GINGIVITIS; HUMAN; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ANTICONVULSANTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; GABA AGENTS; GINGIVAL HYPERTROPHY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENYTOIN; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 0035724471     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2001.00869.x     Document Type: Article

References (81)

1. Gingival enlargement
2. Local and systemic actions of drugs and other chemical agents on periodontal tissues
3. Classification of periodontal diseases
4. Gingival enlargement induced by drugs
5. Incidence of diphenylhydantoin hyperplasia
6. The treatment of epilepsy with sodium diphenylhydantoinate
7. Gingival enlargement induced by phenytoin
8. Drug-induced gingival overgrowth: Old problem, new problem
9. Phenytoin as a risk factor in gingival hyperplasia
10. Gingival hyperplasia induced by cyclosporin A. A report of two cases
11. Cyclosporine-induced gingival hyperplasia. Case report and literature review
12. Cyclosporin A - Usefulness, risks and mechanism of action
13. Gingival overgrowth in cyclosporine A treated multiple sclerosis patients
14. Initial observation that cyclosporin-A induces gingival enlargement in man
15. Positive correlation between blood cyclosporin A level and severity of gingival overgrowth in rats
16. Factors related to the incidence and severity of cyclosporin-induced gingival overgrowth in transplant patients. A longitudinal study
17. Gingival overgrowth in renal transplant patients administered cyclosporin A in mixture or in capsulke form. A longitudinal study
18. Clinical assessment of gingival hyperplasia in patients treated with nifedipine
19. Gingival hyperplasia associated with nifedipine therapy
20. Nifedipine-induced gingival hyperplasia. A histochemicall and ultrastructural study
21. Gingival hyperplasia caused by nifedipine. A preliminary report
22. Calcium channel blockers and gingival overgrowth
23. Gingival hyperplasia caused by verapamil
24. Incidence of verapamil-induced gingival hyperplasia in a dental population
25. Verapamil-induced gingival overgrowth. A clinical, histologic and biochemic approach
26. Gingivahyperplasi forarsaget af behandling med verapamil
27. Calcium antagonist-induced gingival hyperplasia
28. Gingival overgrowth induced by diltiazem
29. Clinical assessment of gingival size among patients treated with diltiazem
30. Cardizem-induced gingival hyperplasia
31. Gingival hyperplasia. A side effect of nifedipine and diltiazem
32. Hyperplastic gingivitis during diltiazem therapy
33. The treatment of epilepsy with sodium diphenylhydantoinate
34. The effect of anticonvulsant drugs upon the gingiva: A series of analyses of 1048 patients
35. Evaluation of the prevalence of side effects of phenobarbital in the Champagne-Ardenne region (France)
36. Hyperplastic gingivitis in a child receiving sodium valproate treatment
37. Valproate-induced stomatitis
38. Vigabatrin-induced gingival overgrowth
39. Anticonvulsants
40. Neuromuscular diseases
41. Effects of antiepileptic drug treatment with carbamazepine or phenytoin on the oral state of children and adolescents
42. Gingival hyperplasia induced by nifedipine
43. Drug induced gingival overgrowth. Clinical features and possible mechanisms
44. Crevicular fluid interleukin-1β, tumor necrosis factor-α, and interleukin-6 levels in renal transplant patients receiving ciclosporine A
45. Phenytoin-induced gingival overgrowth in institutionalized epileptics
46. Proteoglycans and glycosaminiglycans in phenytoin induced gingival overgrowth
47. Drugs and periodontium
48. Nifedipine inhibits calcium uptake of nifedipine-sensitive gingival fibroblast
49. Effect of calcium-channel blockers on cell proliferation, DNA synthesis and collagen synthesis of cultured gingival fibroblasts derived from human nifedipine responders and non-responders
50. Effects of dilantin on monocytic growth factors
51. Gingival hyperplasia. A possible side effect of nifedipine
52. Site-specific variations in metabolism by human fibroblasts exposed to nifedipine in vitro
53. Comparative effects of cyclosporin on glycosaminoglycan synthesis by gingival fibroblasts
54. Evidence that cyclosporine, phenytoin and dihydropiridines elicit overgrowth by different mechanisms
55. Diphenylhydantoin-induced gingival overgrowth in man: A clinico-pathological study
56. Seizures and epilepsy
57. Epilepsias
58. Fármacos antiepilépticos y anticonvulsivantes
59. Complications following the use of sodium diphenylhydantoinate (Dilantin) therapy
60. Diphenylhydantoin gingival hyperplasia
61. The drug therapy epilepsy
62. Diphenylhydantoin-induced gingival hypertrophy. Its relationship to dose and serum level
63. Incidence of diphenylhydantoin gingival hyperplasia
64. Prevalence and risk of gingival enlargement in patients treated with nifedipine
65. The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients
66. Periodontal disease in pregnancy. I - Prevalence and severity
67. Comparative classifying efficiency of normal and power brushing
68. Periodontal probing: What does it mean?
69. Phenytoin-induced gingival overgrowth incidence is dependent upon co-medication
70. The size of a clinical trial
71. Oral health in non-institionalized epileptic children with special reference to phenytoin medication
72. Risk factors in phenytoin-induced gingival hyperplasia
73. Plasma and saliva concentrations of phenytoin and 5-(4hydroxyphenyl)-5-phenylhydantoin in relation to incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients
74. Developement of phenytoin-induced gingival overgrowth in non-institiutonalized epileptic children subjected to different plaque control programs
75. Prevention of phenytoin associated gingival enlargement: A 15-month longitudinal study
76. Prevalence of gingival overgrowth induced by calcium channel blockers: A community-based study
77. Factors influencing phenytoin-induced gingival enlargement
78. Incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients in general medical practice
79. The effect of multiple therapy on the expression of phenytoin-induced gingival overgrowth
80. Regresion of phenytoin-induced gingival overgrowth after with withdrawal of medication